Goldman initiated coverage on Vaxcyte with a new price target
$PCVX
Biotechnology: Pharmaceutical Preparations
Health Care
Goldman initiated coverage of Vaxcyte with a rating of Buy and set a new price target of $135.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/22/2025 | Overweight | Cantor Fitzgerald | |
| 12/20/2024 | $135.00 | Buy | Goldman |
| 12/7/2023 | $69.00 | Buy | Mizuho |
| 4/18/2023 | Outperform | TD Cowen | |
| 1/3/2023 | $52.00 → $58.00 | Buy | Needham |
| 12/15/2022 | $66.00 | Buy | Guggenheim |
| 11/17/2022 | $69.00 | Buy | BTIG Research |
| 12/29/2021 | $50.00 | Buy | Jefferies |